Online inquiry

IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ774MR)

This product GTTS-WQ774MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LOXL2 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002318.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ774MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2414MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ8864MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ1228MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ15146MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ1542MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ3904MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ8560MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ7658MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW